The North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on implementation of NICE TA920 & TA927: Tofacitinib for active Ankylosing Spondylitis & Glofitamab for B-cell lymphoma, as outlined in the consultation document.
Comments are welcomed from across the system, including residents and patients of the NENC. Comments will be returned to the medicines committee, or its sub-committee, and used to inform implementation of the decisions in NENC.
This consultation will run for two weeks and closes at 5pm on Thursday 2nd November 2023. Take part by visiting the consultations page.